Compare Super Micro Computer Inc (SMCI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Micro Computer Inc vs BIO-TECHNE Corp — how do they compare? Super Micro Computer Inc trades at $43.41 (market cap $29.52B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Super Micro Computer Inc is far larger — about 2.6× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Super Micro Computer Inc for 19 Days and BIO-TECHNE Corp for 63 Days on average.
| SMCI | TECH | |
|---|---|---|
Market Cap | $29.52B | $11.37B |
Volume | 40,358,151 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $57.98 | $72.61 |
52-Week Low | $20.53 | $43.31 |
Typical Hold Time | 19 Days | 63 Days |
Enterprise Value | $34.99B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $44.95, up 3.43% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $22B to $39.1B projected for 2026 and consistent earnings beats. Recent AI server demand and NVIDIA Vera Rubin shipments highlight growth catalysts, though RSI levels suggest potential overbought conditions near-term.
Outlook remains positive given AI infrastructure expansion and strong financials, but risks include margin pressure, competitive threats, and ongoing DOJ investigation. Analyst consensus targets $42.33 with 36% buy ratings, indicating cautious optimism despite the stock trading above target. Valuation appears reasonable with P/E of 13.79 and P/S of 0.8.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
